Experts In The News
UNLV research shows a decline from the pandemic surge of Californians moving to Nevada.
Las Vegas’ history is filled with infamous stories of mobsters leaving their mark on the city throughout the years, and of course, they also need places to live while in Sin City.
The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.
The UNLV Athletics program received a $1.05 million donation for its “Rebel Up” campaign. The donation is thanks to Diana Bennett. UNLV Athletics says Bennett served as the chair of the UNLV Foundation Board of Trustees from 2020-2022 and has been a board member since 2008. The donation will establish the creation of the Diana Bennett Career Development Program for Women’s Sports.
A gaming executive has committed over $1 million to help launch a new career development program at UNLV for women student-athletes. Paragon Gaming CEO Diana Bennett's donation will go toward creating the new initiative, which is set to launch this coming fall semester, UNLV announced Wednesday.
For more than 30 years, Nevada has asked households to recycle 25 percent of qualified materials — plastics, paper, aluminum and more. It’s not a mandate. And in 2021, Nevada’s division of environmental protection said 24 percent had been reached. That means just one out of four recyclable materials are thrown into the light-blue recycle bin in Southern Nevada. Part of the reason it might not be more is that people still have questions over what is and what isn’t recyclable.
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.
The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.